Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 3:15:20420188241274310.
doi: 10.1177/20420188241274310. eCollection 2024.

Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis

Hareer Fatima  1 , Hussain Sohail Rangwala  1 , Muhammad Saqlain Mustafa  1 , Muhammad Ashir Shafique  2 , Syed Raza Abbas  3 , Burhanuddin Sohail Rangwala  1
Affiliations

Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis

Hareer Fatima et al. Ther Adv Endocrinol Metab. .

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common liver condition affecting 25%-40% of the worldwide population. NAFLD is traditionally related to obesity and metabolic disorders. NAFLD can also affect non-obese individuals, termed "lean NAFLD" (LN), who exhibit a paradoxical combination of physical leanness and metabolic obesity. Factors contributing to LN remain unclear, necessitating further research. This analysis aims to understand LN's prevalence and metabolic characteristics compared to obese NAFLD (ON) populations.

Methods: This meta-analysis searched various databases until August 1, 2023. Inclusion criteria involved observational studies comparing LN with overweight/obese NAFLD. Data extraction included baseline characteristics, disease occurrence, metabolic profile, and clinical parameters-statistical analysis employed calculating risk ratios (RR) and standard mean differences.

Results: Twenty-five studies were analyzed. LN is associated with lower prevalence in both NAFLD (RR 0.27, 95% confidence interval (CI) 0.14-0.52, p = <0.0001) and total (RR 0.27, 95% CI 0.15-0.51, p < 0.0001) population. LN had lower diabetes mellitus (RR 0.78, 95% CI 0.71-0.87, p < 0.00001), dyslipidemia (RR 0.87, 95% CI 0.79-0.95, p = 0.002), hypertension (RR 0.80, 95% CI 0.74-0.87, p < 0.00001), and metabolic syndrome (RR 0.45, 95% CI 0.31-0.64, p < 0.00001) compared to those with ON. The LN group's lipid profile, blood pressure, and other clinical parameters were favorable compared to ON.

Conclusion: The prevalence of NAFLD among lean and non-lean individuals varies by region. Our analysis revealed that LN is associated with lower metabolic diseases, fasting blood sugar, blood pressure, and a more favorable lipid profile compared to ON.

Keywords: NAFLD; lean NAFLD; metabolic profile; prevalence.

Plain language summary

NAFLD prevalence and its characteristics among obese vs lean population Non-alcoholic fatty Liver Disease (NAFLD) is a prevalent liver condition affecting a substantial portion of the global population, commonly linked to obesity and metabolic disorders. However, a subset of individuals with NAFLD, termed “lean NAFLD” (LN), challenges the conventional association by presenting with physical leanness despite metabolic obesity. The factors contributing to this condition are not well understood, prompting this meta-analysis to explore the prevalence and metabolic characteristics of LN compared to obese NAFLD (ON) populations. The study, conducted through August 1st, 2023, analyzed 25 studies meeting inclusion criteria, which involved observational studies comparing LN with Overweight/Obese NAFLD. Data extraction included baseline characteristics, disease occurrence, metabolic profiles, and clinical parameters. Statistical analysis utilized risk ratios (RR) and standard mean differences. The results indicated that LN is associated with a significantly lower prevalence in both the NAFLD and general populations. LN demonstrated lower occurrences of diabetes (DM), dyslipidemia, hypertension, and metabolic syndrome compared to ON. Additionally, the LN group exhibited a more favorable lipid profile, blood pressure, and other clinical parameters in comparison to the ON group. In conclusion, the prevalence of NAFLD varies among lean and non-lean individuals across different regions. The meta-analysis revealed that LN is linked to a lower occurrence of metabolic diseases, lower fasting blood sugar levels, lower blood pressure, and a more favorable lipid profile compared to those with ON. These findings contribute valuable insights into the distinct metabolic characteristics of LN, shedding light on potential avenues for further research and clinical considerations in the understanding and management of NAFLD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flowchart.
Figure 2.
Figure 2.
Forest plot for lean NAFLD versus obese NAFLD for prevalence in total NAFLD population: (3.1.1) Asia; (1.1.2) Europe; (3.1.3) North America. NAFLD, non-alcoholic fatty liver disease.
Figure 3.
Figure 3.
Forest plot for lean NAFLD versus obese NAFLD for prevalence in total population: (2.5.1) Asia; (2.5.2) Europe; (2.5.3) North America. NAFLD, non-alcoholic fatty liver disease.
Figure 4.
Figure 4.
Forest plot for lean NAFLD versus obese NAFLD for systemic diseases: (1.1.1) Diabetes; (1.1.2) Dyslipidemia; (1.1.3) Hypertension; (1.1.4) Metabolic Syndrome. NAFLD, non-alcoholic fatty liver disease.
Figure 5.
Figure 5.
Forest plot for lean NAFLD versus obese NAFLD for lipid profile: (2.1.2) HDL; (2.1.3) LDL; (2.1.4) Triglycerides. HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease.
Figure 6.
Figure 6.
Forest plot for lean NAFLD versus obese NAFLD for BP: (2.3.1) Systolic BP; (2.3.2) Diastolic BP. BP, blood pressure; NAFLD, non-alcoholic fatty liver disease.
Figure 7.
Figure 7.
Forest plot for lean NAFLD versus obese NAFLD for waist circumference. NAFLD, non-alcoholic fatty liver disease.
Figure 8.
Figure 8.
Forest plot for lean NAFLD versus obese NAFLD for fasting blood sugar. NAFLD, non-alcoholic fatty liver disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 2023; 29: S32. - PMC - PubMed
    1. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 2015; 7(6): 846–858. - PMC - PubMed
    1. Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications—what the non-specialist needs to know. Diabetes Obes Metab 2022; 24(Suppl. 2): 3–14. - PubMed
    1. Tang ASP, Chan KE, Quek J, et al.. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: an updated meta-analysis with 135,602 individuals. Clin Mol Hepatol 2022; 28(3): 483–496. - PMC - PubMed
    1. Tan DJH, Ng CH, Lin SY, et al.. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol 2022; 23(4): 521–530. - PMC - PubMed

LinkOut - more resources